I would like to cite for my hon. Friend and the House the Library briefing, which shows that it is not exactly as cut and dried as the hon. Member for Torbay (Kevin Foster) seemed to think. It tells us that the Competition and Markets Authority took action against pharmaceutical companies with regards to generic pricing, and that GlaxoSmithKline and a number of other companies were fined £45 million when it was found that payments had been made in order to prevent the antidepressant medication, Paroxetine, being offered on the generics market. GSK is a great pharma company for coming up with new drugs, but it crossed the line in this case, according to the Library briefing, so it is not always either/or when it comes to these pharma companies.
Health Service Medical Supplies (Costs) Bill
Proceeding contribution from
Rob Marris
(Labour)
in the House of Commons on Monday, 24 October 2016.
It occurred during Debate on bills on Health Service Medical Supplies (Costs) Bill.
About this proceeding contribution
Reference
616 c107 Session
2016-17Chamber / Committee
House of Commons chamberSubjects
Librarians' tools
Timestamp
2020-04-14 16:59:38 +0100
URI
http://hansard.intranet.data.parliament.uk/Commons/2016-10-24/16102449000039
In Indexing
http://indexing.parliament.uk/Content/Edit/1?uri=http://hansard.intranet.data.parliament.uk/Commons/2016-10-24/16102449000039
In Solr
https://search.parliament.uk/claw/solr/?id=http://hansard.intranet.data.parliament.uk/Commons/2016-10-24/16102449000039